Data completeness
1/8 — Limited
PROKETAZINE (carphenazine maleate) by Thayer Medical is clinical pharmacology dextromethorphan: dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties.
Drug data last refreshed 16h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROKETAZINE (Carphenazine Maleate) is an oral tablet combining dextromethorphan (a non-narcotic antitussive) and promethazine (a phenothiazine-derived antihistamine with sedative and antiemetic properties). It is indicated for cough suppression and relief of associated symptoms in patients requiring central cough threshold elevation without opioid exposure. The fixed-dose combination leverages dextromethorphan's rapid GI absorption and 3–6 hour duration with promethazine's H1-blocking and sedative effects.
Pre-Launch
Pre-launch stage suggests early-stage brand building, field force expansion, and establishment of sales and marketing infrastructure for OTC or Rx antitussive market entry.
Mechanism of Action
CLINICAL PHARMACOLOGY Dextromethorphan: Dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties. The drug acts centrally and elevates the threshold for coughing. It is about equal to codeine in depressing the cough reflex. In…
Indications
Worked on PROKETAZINE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.